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ABSTRACT 
Objective: To study the Therapeutic drug monitoring and pharmacokinetics of marketed antibiotics formulation by developing a sensitive and 
specific Bioanalytical Chromatographic method. 
Methods: In the present study, we developed a rapid, sensitive and selective chromatographic method for simultaneous estimation of Cefoperazone 
(CEF) And Sulbactam (SAL) in male Wistar rat plasma. A novel liquid phase extraction method has adopted the preparation of plasma sample 
preparation. The CEF and SAL were eluted on a peerless Basic C18 (25 cm; 4.6 mm x 5 µm) column maintained at controlled environmental 
conditions. The gradient mobile phase comprised of 10 mmol ammonium acetate and acetonitrile. A UV detector was set at 250 nm and retention 
times for CEF and SAL were approximately 5.6 and 14.2 min, respectively. The proposed HPLC method was validated according to the US FDA 
guidelines with respect to the linearity, accuracy, precision, detection and quantitation limits, robustness and specificity. 
Results: Calibration curves of CEF and SAL were linear across the concentration range of 600-1000 and 6-10 µg/ml, with correlation coefficients 
(r2)>0.9977 and (r2)>0.9987, respectively. The limits of detection for CEF and SAL were 70.48 and 0.35 µg/ml, respectively. Additionally, CEF and 
SAL were stable in plasma for at least 24 h when stored at room temperature and 2-8 °C.  
Conclusion: The developed chromatographic method was effectively utilized to measure the plasma CEF and SAL concentrations in a 
pharmacokinetics study after intravenous injection to the healthy male Wistar rats.  
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INTRONDUCTION 
Antibiotics are chemically synthesized antimicrobial molecules 
regularly prescribed over the times for the prevention and 
treatment of various infectious diseases. Additionally, now day’s 
antibiotic and/or antibiotics combinations (e. g. 
cefoperazone/sulbactam; sulfamethoxazole/trimethoprim and 
amoxicillin/clavulanate) are also frequently used to treat severe 
infections such as abdominal, urinary tract infections and 
respiratory disorders [1, 2]. Appropriate dosing of the antibiotics is 
of utmost significance for clinical management. Besides, attaining 
the correct therapeutic level is of high importance for avoiding the 
development of antimicrobial resistance. Additionally, it also affects 
the drug distribution, metabolism and clearance. Therefore, guided 
management with therapeutic drug monitoring (TDM) helps to 
maximize the efficiency of the antibiotic and similarly to reduce 
adverse side effects, likewise enhancing the clinical outcomes. By 
knowing these consequences, for effective antibiotic TDM, in the 
present study bio-analytical method was developed and validated 
for commonly prescribed antibiotics combinations of cefoperazone 
(CEF) and sulbactam (SAL) [3-5]. 
Various active analysts and researchers took numerous efforts to 
develop the analytical method for the simultaneous estimation of the 
CEF/SAL in the biological matrix. A high-performance liquid 
chromatography (HPLC) [6-10], high-performance thin-layer 
chromatography (HPTLC) [11, 12] gas chromatography (GC), liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) [13] and 
ultraviolet-visible spectroscopy (UV-VIS) [14, 15] spectro-
photometric method have been developed and explored for 
simultaneous estimation of the antibiotics combinations. Among the 
available analytical techniques, HPLC found to be a helpful tool for 
quality control and assessment of antibiotics because of its 
simplicity, few processing requirements and low cost. Additionally, 
it also has been commercially used to develop a chromatographic 
fingerprint for various synthetic, semi-synthetic antibiotics 
molecules and formulations.  
CEF is chemically (6R,7R)-7-[[(2R)-[[(4-Ethyl-2,3-dioxo-1-
piperazinyl)carbonyl]amino] (4-hydroxy phenyl) acetyl] amino]-3-
[[(1-methyl-1Htetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo-
oct-2-ene-2-carboxylic acid. CEF is a third-generation cephalosporin 
antibiotic routinely prescribed for Pseudomonas bacterial infections 
[15]. Additionally, it also used for the treatment of respiratory 
infection, urinary tract infection and female genital tract infection. It 
is a white color crystalline powder with a log P value of-0.74 and 
two ionizable groups (pKa = 2.55 and 9.55). Therefore, CEF exists 
mainly as a mono-anionic at a physiological pH. Different analytical 
techniques have been well documented in the scientific literature for 
determining the CEF in the various matrix such as reverse phase HPLC 
[7-10], HPTLC [11, 12] and UV spectrophotometry [14, 15]. SAL is a 
semi-synthetic beta-lactamase inhibitor and is chemically (2S, 5R)-3,3-
dimethyl-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0] heptane-2-
carboxylic acid. It is administered in combination with β-lactam 
antibiotics (e. g. penicillin and cephalosporin) to inhibit β-lactamase 
[15]. It is a small molecule (233.24 g/mol) with a log P value of-0.92 
and freely soluble in water (48.5 mg/ml). Several analytical 
techniques have been reported to determining the SAL in 
combination, including HPLC [7-10], HPTLC [11, 12], LC-MS/MS [13] 
and UV spectrophotometry [14, 15] for the quantitative 
determination of SAL in the pharmaceutical dosage form, bulk drug 
and plasma. 
To the finest of our information, no efforts have been made to 
analyze and detect the CEF and SAL combinations in plasma using a 
suitable chromatographic method. Therefore, in the present study, 
we developed and validated a bio-analytical method for the 
simultaneous detection of CEF and SAL in male Wistar rats. 
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Additionally, the method utilizes the efficient and less time-
consuming isolation process i.e. liquid phase extraction (LPE) for 
simultaneous detection of CEF and SAL. Furthermore, the developed 
method was validated using the Food and Drug Administration 
(FDA), United States (US) guidelines [16]. 
MATERIALS AND METHODS 
Chemical and reagent  
CEF and SAL were as obtained as a gift sample from Emcure Bhosari, 
Pune. Cefoperazone-Sulbactam injection (1:0.5) purchased from a 
local medical shop, Pune. HPLC grade ammonium acetate and 
acetonitrile were obtained from Merck Specialties Private Limited, 
Mumbai, India. Ultrapure water was obtained from a Milli-Q 
Apparatus (Millipore, Barnstead). Normal Saline (Euroline®) was 
obtained from Eurolife Healthcare, Pune. Syringe filters (0.22 µm), 
filter papers (0.45 µm) and ethylenediamine tetraacetic acid (EDTA) 
tubes were obtained from Merck Specialties Private Limited, 
Mumbai, India. Male Wistar Rats (200-220 gm) were purchased 
from Agharkar Research Institute, Pune. 
Animals 
Healthy Wistar male rats weighing 200-220 g were procured from 
Agharkar Research Institute, Pune. Obtained rats were maintained in 
single polypropylene cages at a steady temperature (25±1 °C) and 
humidity (45-55 %) with 12 h dark-light cycles. The rats were fasted 
but supplied with free access to water overnight previous to the 
start of the study. All animal procedures were implemented as per 
the Guidelines for the Care and Handling of Laboratory Animals of 
CPCSEA (Committee for the Purpose of Control and Supervision of 
Experiments on Animals) and sanctioned by the Animal Ethics 
Committee of Bharati Vidyapeeth Deemed to be University, Poona 
College of Pharmacy registered with CPCSEA (Reg. No. 
1703/PO/Re/S/01/CPCSEA). 
Chromatographic system 
The method was developed and validated on an LC-4000 Series Low-
pressure gradient HPLC system equipped with a quaternary pump 
(PU-2080+), online degasser(PU-4180), HPLC column oven (HCO-02) 
and coupled with a dual-wavelength absorbance detector(UV-4075). 
Data acquisition and processing were carried out using Chrom NAV 
2.0 software (Chromatography Data System (CDS)). Chromatographic 
separation was performed on a Peerless basic C18 (25 cm x 4.6 mm x 
5 µm Peerless Silica 3 µm particle size) analytical column equipped 
with a guard column (Column Saver; 0.5μm/10pk). Chromatographic 
separation was performed at ambient temperature (25 °C±2 % and 45 
%±2 % humidity). Gradient elution was performed using mobile phase 
A consisting of 10 mmol Ammonium Acetate, and mobile phase B 
consisting of acetonitrile. The gradient was initiated at 0 % mobile 
phase B upon injection and increased up to 100 % by scouting 
gradient curve over 20 min. The column was re-equilibrated at 5 % 
mobile phase A for five minutes prior to each injection. Single 
wavelength detection was utilized at a UV absorbance of 250 nm and 
the flow rate was set at 1 ml/min. 
Preparation of stock solutions, working solutions and 
calibration standards 
CEF (1000 μg/ml) and SAL (100 μg/ml) standard were prepared 
with normal saline. Subsequent working standards were prepared to 
contain 600/6, 700/7, 800/8, 900/9 and 1000/10 μg/ml of CEF and 
SAL by serial dilutions with Millipore water.  
Sample preparation 
Liquid phase extraction 
Liquid phase extraction (LPE) was performed as a method described 
by Veillette et al., (2016) with few modifications [17]. Briefly, the 50 
μl of rat plasma was added carefully to 800 μl acetonitrile and 
subjected to the vortex (Spinix vortex shaker, Tarsons) for five 
minutes. The obtained mixture was centrifuged (Eppendorf AG 
22331, Hamburg) at a constant speed (8000 RPM) for five minutes. 
After centrifugation supernatant was carefully pipette out and 
filtered through a 0.22 μm syringe filter. Obtained filtrate (20 µl) 
used as such for the HPLC analysis. 
Extraction efficiency 
The extraction efficiency of CEF and SAL from rat plasma was 
estimated at CEF concentrations of 600, 700 and 800 μg/ml and at 
SAL concentrations of 6, 7 and 8 μg/ml. The extraction efficiency 
was calculated by co-relating the CEF and SAL drug standards with 
the peak area of extracted plasma samples (three samples at 
individual concentration level).  
Linearity 
The linearity of the method was established by a five-point 
concentration calibration curve, achieved by spiking a series of 
standard mixtures of CEF (600-1000 μg/ml) and SAL (6-10 μg/ml) 
into rat plasma, extracting both drugs by LPE and analyzing by 
triplicate injections. Calibration curves for spiked plasma samples 
were then acquired by plotting the peak areas against their 
respective concentrations. Linear least-squares regression was 
applied, and the slope, intercept, correlation coefficient (r), and 
coefficient of determination (R2) was determined. 
Recovery and precision 
Analytical recovery and precision were assessed by the analysis of 
five separately prepared samples of the low (LLOQ), medium, and 
high drug concentration spiked plasma samples. Intra-day data of 
the five separately prepared samples was collected over a single run, 
while inter-day data of another five separately prepared five 
samples were collected over four separate days. Recovery was 
calculated using the following Equation 1 and expressed in terms of 
percentage. Intra-and inter-day precision expressed as the 
coefficient of variation. 
Recovery =  
                            
                          
  100. . Eq. 1 
Specificity/selectivity 
The selectivity/specificity of the analytical method was investigated 
by confirming the complete separation and resolution of both the 
analytes in the standard solution and spiked rat plasma samples. 
Moreover, the retention times of endogenous plasma components 
were compared with those of CEF and SAL to assess for interference. 
LOD and LOQ 
The limit of detection (LOD) and the limit of quantification (LOQ) 
were well described by the US FDA guidelines for bio analytical 
method validation [16]. The LOD and LOQ are estimated by the 
signal to noise method. 
Stability of CEF and SAL in the extraction fluid  
The stability of CEF and SAL in the LPE extraction fluid was 
determined at room temperature (25 °C±5) as well as refrigerated at 
(2-10 °C) conditions for up to 24 hr (i.e., over a period greater a 
typical daily run).  
Analysis of marketed product 
There are several crucial challenges such as low sample volume, 
tedious sample preparation variable detection limits and 
development of a robust analytical method to perform TDM in wide 
patient groups. CEF and SAL are having a large volume of 
distribution and mainly excreted via bile and urine, respectively 
particularly, the pharmacokinetics of CEF is highly variable and thus 
need close TDM during the treatment period [18, 19]. Additionally, 
the pharmacokinetic data in pediatric patients are limited and thus it 
makes TDM and dose adjustment more challenging [20]. By knowing 
this scenario, the pharmacokinetic profile of the marketed CEF/SAL 
combination was studied using the developed analytical method. 
Marketed CEF/SAL combination (1:0.5) was administered to male 
Wistar rats (n=4) via intravenous injection. Blood samples were 
collected from retro-orbital puncture after 0.5 h of administration. 
Blood samples were collected in the EDTA tubes and centrifuged at 
8000 RPM for five min to collect the plasma. Collected plasma 
samples were kept at 2-10 °C until analysis. The concentrations of 
both the drugs in plasma samples were quantified using the 
developed analytical method.  
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RESULTS AND DISCUSSION 
Chromatographic separation of CEF and SAL in the biological fluid 
was performed using reverse phase HPLC method. Initially, various 
mobile phases were explored to gain maximum response for CEF 
and SAL. Chromatographic methods for the separation of antibiotic 
combination in biological solutions have used inorganic buffers in 
the mobile phase(s) to maintain low pH. Thus, we initiated method 
development with a combination of phosphate buffer (pH 2.5) and 
acetonitrile. Various ratios of phosphate buffer and acetonitrile were 
investigated. The response of low pH mobile phase was much more 
selective and sensitive for SAL whereas it was opposing for CEF. 
Therefore, by considering the pKa values of CEF (pKa 3.4) and SAL 
(pKa 2.86) the mobile phase composition was modified to 10 mmol 
ammonium acetate (pH 5) and acetonitrile. The response of the 
modified mobile phase (high pH) was much more selective and 
sensitive for both the compounds. Other chromatographic 
conditions, such as the sample injection volume and flow rate, 
column saturation time, total run length were also optimized to give 
accurate, precise and reproducible retention time, proportioned 
peak shape and better separation for both drugs. The method was 
optimized to analyze both drugs with no interference from plasma 
components. The retention time (Rt) for CEF and SAL was 5.6 and 
14.2 min for the 10 mmol ammonium acetate (pH 5) and acetonitrile 
mobile phase at controlled environmental conditions. The run time 
of the chromatogram was 20 min. The distance between the peaks 
was 8.6 min. The peak shape was sharp and more symmetrical. The 
optimized chromatographic conditions are shown in table 1. 
 
Table 1: Linear regression data, LOD, and LOQ for the antibiotics using the proposed HPLC method (n=3) 
Parameters CEFO SAL  
Slope  210.64  152116.8 
Intercept  0.6949  1.521 
Correlation coefficient (r) 0.99779  0.99826 
Coefficient of determination (R2)  0.9865  0.9965 
Calibration Range (μg/ml)  600-1000  6-10 
LOD(ppm) 70.4871787 10.35527949 
LOQ(ppm) 213.5975112  1.076604516 
*LOD = Limit of detection, LOQ = Limit of quantification 
 
Preparation of working standard solution  
Accurately weighed CEF (100 mg) and SAL (10 mg) were transferred 
to 100 ml volumetric flask and a sufficient amount of saline water 
was added to attain the concentration of 1000 μg/ml CEF and 100 
μg/ml SAL. The prepared standard solution was diluted further to 
obtain the CEF and SAL in the concentrations range of 600-
1000μg/ml and 6-10 μg/ml, respectively.  
Plasma extraction sample preparation 
To establish an efficient method for the extraction of CEF and SAL 
from plasma, several purification methods were explored. Initially, 
the various extraction solvents such as tricholoroacetic acid (1-15 
%), methanol, 10 % per chloric acid, ethyl acetate, chloroform and 
dichloromethane were used for sample preparation. These 
processes were proved to be labor-intensive, prone to emulsion 
formation, and consumed relatively large volumes of high-purity 
solvents with expensive disposal requirements and thus did not 
appear an attractive one for use with a large number of samples. By 
using these high-purity solvents the resulting chromatogram of 
blank plasma (no drug) showed numerous peaks that would 
interfere with the quantization of this drug at 250 nm. Also, 
recoveries for both CEF and SAL were below 90 % with this method, 
The highly polar nature (log P ≤ 1) and solubility characteristics of 
CEF and SAL (CEF is in sodium salt form which is freely soluble in 
water and SAL is freely soluble in water and slightly soluble in 
ethanol and dilute acids) suggested that the use of a liquid phase 
extraction method to separate drug from plasma components using 
a polar solvent such as acetonitrile/10 mmol ammonium acetate 
eluent would not only be reasonable, but more appropriate and 
applicable. Until it was determined that the 800 µl of Acetonitrile 
maximized the extraction of both components while minimizing the 
elution of unwanted serum constituents. When blank serum (no 
drug) was extracted using LPE, the resulting chromatogram 
exhibited a vastly improved baseline, free of interfering plasma 
components at a detection wavelength of 250 nm (fig. 1). 
 
 
Fig. 1: Chromatogram of blank rat plasma 
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Specificity of the method was confirmed by the complete baseline 
separation of all analytes, as well as the absence of interfering peaks 
at the retention times of CEF (4.2 min), SAL (14.2 min) in both a 
spiked sample (fig. 2) and in a sample from a rat 0.5 h after receiving 
a 1.5 g intravenous dose of injection (1:0.5g Cefoperazone-
Sulbactam) (fig. 3). 
 
 
Fig. 2: Chromatogram of spiked plasma containing 600:6 µg/ml, CEF and SAL, resp 
 
 
Fig. 3: Chromatogram after receiving a 1:0.5 g dose of formulation, (i.e. 1.0 g CEF and 0.5 g SAL) 
 
Linearity, LOD and LOQ 
Table 1 shows the parameters of the calibration curves, as well as 
the LOD and LOQ for the developed method. The linearity of 
measurement was evaluated by analyzing standard solutions of CEF 
and SAL in and the range of 600-1000 μg/ml and 6-10 μg/ml for 
both drugs respectively and calibration plot was constructed. The 
plots revealed that the residual values of each standard sample used 
to build the calibration curve were scattered randomly about zero, 
and exhibited no trends of expansion with respect to concentration. 
As a result, it was determined that the standard curves for CEF and 
SAL were adequately described by least-squares linear regression 
analysis over the ranges studied. 
LOD and LOQ of CEF and were determined by the calibration curve 
method. Detection limits were determined as a signal/noise ratio 
being at least five. Analyte peak should be identifiable, discrete, and 
reproducible with a precision of 20 % and accuracy of 80-120 %. 
The lower limit of quantification was 70.48 μg/ml for CEF (S/N>5) 
and 0.35μg/ml for SAL (S/N>5), respectively. 
Extraction yield, recovery and precision 
The data for the extraction yield of CEF and SAL from plasma, as 
well as the mean intra-and inter-day recovery and precision data 
are summarized in table 2. At all concentrations, the extraction 
yield was 90% or greater, and the variation in precision was less 
than 5%. 
Stability 
The stability of CEF and SAL in the LPE extraction fluid was 
determined at temperatures ranging from-20 °C to room temperature. 
We sought to ascertain that there was sufficient stability of both CEF 
and SAL in the LPE eluent fluid to enable the analysis of large batches 
of samples under either refrigerated (2-8 °C) or room temperature 
(20-25 °C) conditions. Results demonstrated that samples eluted 
from LPE by using 800 µl Acetonitrile were stable, defined as no 
reduction in peak areas and no detection of new peaks when stored 
for 24 h at either refrigerated (2-8 °C) or room temperature. The 
results are summarized in table 3. 
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Precision (% CV) 
CEFO      
600 90.9±3.05 95.03 0.38 87.39 0.45 
700 91.1±2.01 97.43 0.44 89.34 0.43 
800 90.31±1.01 93.21 0.39 86.33 0.34 
SAL      
6 100±1.127 103.23 1.03 98.30 1.23 
7 99.98±4.27 101.21 2.34 97.56 2.34 
8 98.67±3.23 100.03 1.75 86.87 1.45 
*conc = concentration, SD = standard deviation and CV=coefficient of variation  
 
Table 3: Stability of CEF and SAL by liquid phase extraction at two different storage conditions (n=3) 
Known conc (μg/ml) Initial conc (μg/ml) 
(mean±SD) 
Conc at 24 h storage at room 
temperature (μg/ml) (mean±SD) 
Conc at 24 h storage 2-8 °C (μg/ml) 
(mean±SD) 
CEFO    
600 540±0.23 538±0.21 541±0.23 
700 630±1.05 632±2.09 630±0.45 
800 720±1.23 721±1.29 718±2.23 
SAL    
6 6.03±0.23 6.83±0.23 6.70±1.35 
7 6.99±0.21 6.89±0.21 7.86±1.54 
8 7.89±0.36 8.89±1.36 7.86±1.38 
*conc = concentration, SD = standard deviation 
 
Application of the method 
To assess the clinical applicability in a pharmacokinetic analysis, 
the developed method was used to quantify the concentrations of 
CEF and SAL in plasma samples obtained from healthy male Wister 
rats. A demonstrative chromatogram from a collected plasma 
sample is shown in fig. 2. Additionally, there were no endogenous 
interfering peaks in the chromatogram. A non-compartmental 
model was adopted for pharmacokinetic analysis. The three 
pharmacokinetic parameters such as AUC (0-∞), Cmax and t1/2 were 
calculated for CEF and SAL at 0.5 h after an intravenous 
administration of the marketed formulation. The summary of the 
pharmacokinetic analysis is shown in table 4. This highlights the 
importance of the liquid phase extracting technique in bio-
analytical sample preparation. Briefly, the developed bio-
analytical method was found to be more sensitive as compared to 
previously published methods and acts to be more appropriate for 
antibiotics TDM and clinical assessment. 
  
Table 4: Pharmacokinetic parameters of CEF and SAL in male wistar rats following an intravenous injection administration (n=4) 
Pharmacokinetic parameters CEFO (mean±SD) SAL (mean±SD) 
Cmax (μg/ml) 2070.15±40.30 13.31±2.62 
AUC(0-∞) (μg/ml/h) 132261.05±32.35 1610.26±89.23 
t1/2 (h) 24.42±0.12 2.44±1.01 




A novel, precise and robust bioanalytical method was developed 
for the simultaneous estimation of CEF and SAL in plasma samples 
obtained from healthy male Wister rats using a peerless Basic C18 
column with a gradient mobile phase comprised of 10 mmol 
ammonium acetate and acetonitrile. Single wavelength detection 
was utilized at a UV absorbance of 250 nm and the flow rate was 
set at 1 ml/min. The method is highly specific as there was no 
interference observed between chromatograms of blank, standard 
and sample. This method highlights the importance of the liquid 
phase extracting technique in bio-analytical sample preparation. 
Good linearity with the coefficient of correlation 0.99 indicated 
that the proposed method was linear within the range of 600 to 
1000 ppm, 6 to 10 ppm respectively for CEF and SAL. The method 
was found to be accurate as the extraction values observed for CEF 
and SAL was well within the range of 90-100% as shown in table 2 
for intra and inter day. As the stability of CEF and SAL at different 
storage conditions were found to be 2.9% and 3.1% w/w 
respectively as shown in table 3. According to the method 
described herein, the pharmacokinetics of CEF and SAL were 
determined at 0.5 h after an intravenous administration to the 
four healthy male wistar rats found the more sensitive and 
selective method than previously published methods [21-24] as 
shown in table 4. The LOD and LOQ values showed the method 
was sensitive for the simultaneous estimation of CEF and SAL at 
low concentrations also. The method is validated as per the US 
FDA guidelines.  
CONCLUSION 
This article explains a simple, rapid and cost-effective method for 
the simultaneous quantification of CEF and SAL concentrations in rat 
plasma using HPLC coupled with UV-visible spectroscopy. 
Additionally, the method involves a simple and novel liquid phase 
extraction technique to process the bio-analytical samples. The 
method presents several key advantages for assaying the drug 
combination with superior accuracy and high sensitivity. This 
chromatography technique was effectively applied for a 
pharmacokinetic study of CEF and SAL combination following 
intravenous administration in male Wistar rats. The ease of the 
method makes it more appropriate for regular therapeutic drug 
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monitoring and clinical pharmacokinetic investigations of antibiotics 
and its combinations. 
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